Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Trial Recruitment Closes On Novo’s Next Big Semaglutide Bet: Alzheimer’s Disease

Twin EVOKE Studies Aim To Prove Neurological Benefits

Executive Summary

Semaglutide has become a game-changer in type 2 diabetes and overweight patients, but Novo Nordisk is hoping to prove it can also slow cognitive decline in Alzheimer’s disease. It’s a long shot, but two large Phase III studies are now well underway to show just that.

You may also be interested in...

Lilly’s Donanemab, Now At FDA, Poised To Join Alzheimer’s Armamentarium

Lilly expects US approval of the anti-amyloid therapy by the end of the year. Full Phase III data were detailed at AAIC.

Genentech Joins Hunt For ‘Molecular Glue’ Drugs With Orionis

Genentech is broadening its stake in the protein degradation field, following BMS and Merck & Co into molecular glue drugs.

RayzeBio And Genentech Show Interest In Radiopharmaceuticals Continues To Grow

RayzeBio's IPO and Genentech's first buy-in into the field show a wave of next-generation companies hoping to expand the radiopharmaceutical field.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts